A Phase 1b/2 study to assess the safety, tolerability and efficacy of BGB-290 in combination with radiation therapy and/or temozolomide in subjects with first-line or recurrent/refractory glioblastoma
Sponsor: |
BeiGene, Ltd. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAR6842 |
U.S. Govt. ID: |
NCT03150862 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to look at the effects of an investigational anti-cancer drug (BGB-290) in combination with radiation therapy and/or temozolomide in patients with newly diagnosed or recurring glioblastoma. BGB-290 is expected to work by preventing cancer cells from repairing their damaged genes, causing the progression of cancer to slow down.
This study is closed
Investigator
Andrew Lassman, MD
Are you 18 years or older? |
Yes |
No |
Do you have a diagnosis of glioblastoma? |
Yes |
No |
If you were recently diagnosed with glioblastoma, have you received treatment for your glioblastoma other than surgery? |
Yes |
No |
If your glioblastoma has recently recurred, have you only received chemotherapy treatment with temozolomide? |
Yes |
No |